WO2019023347A1 - ANTI-SIRP-ALPHA ANTIBODIES AND ASSOCIATED METHODS - Google Patents

ANTI-SIRP-ALPHA ANTIBODIES AND ASSOCIATED METHODS Download PDF

Info

Publication number
WO2019023347A1
WO2019023347A1 PCT/US2018/043699 US2018043699W WO2019023347A1 WO 2019023347 A1 WO2019023347 A1 WO 2019023347A1 US 2018043699 W US2018043699 W US 2018043699W WO 2019023347 A1 WO2019023347 A1 WO 2019023347A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
human
seq
cdr
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/043699
Other languages
English (en)
French (fr)
Inventor
Jie Liu
Jens-Peter VOLKMER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forty Seven LLC
Original Assignee
Forty Seven LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PL18765224.3T priority Critical patent/PL3658589T3/pl
Priority to CA3071193A priority patent/CA3071193A1/en
Priority to KR1020207005520A priority patent/KR102670957B1/ko
Priority to JP2020504234A priority patent/JP7122370B2/ja
Priority to MX2020000957A priority patent/MX2020000957A/es
Priority to AU2018308364A priority patent/AU2018308364C1/en
Priority to BR112020001653-5A priority patent/BR112020001653A2/pt
Priority to CN201880060680.2A priority patent/CN111448210B/zh
Priority to SG11202000658PA priority patent/SG11202000658PA/en
Application filed by Forty Seven LLC filed Critical Forty Seven LLC
Priority to EP18765224.3A priority patent/EP3658589B1/en
Priority to ES18765224T priority patent/ES2963157T3/es
Publication of WO2019023347A1 publication Critical patent/WO2019023347A1/en
Priority to IL272218A priority patent/IL272218A/en
Anticipated expiration legal-status Critical
Priority to JP2022078181A priority patent/JP7383074B2/ja
Priority to AU2022204618A priority patent/AU2022204618B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • the cell surface protein CD47 on healthy cells and its engagement of a phagocyte receptor, SIRPa constitutes a key "don't eat-me” signal that can turn off engulfment mediated by multiple modalities, including apoptotic cell clearance and FcR mediated phagocytosis. Blocking the CD47 mediated engagement of SIRPa on a phagocyte can cause removal of live cells bearing "eat me” signals.
  • Also disclosed herein is an isolated polynucleotide or set of polynucleotides encoding an isolated antibody disclosed herein, a VH thereof, a VL thereof, a light chain thereof, a heavy chain thereof, or an antigen-binding portion thereof.
  • polynucleotides disclosed herein or a vector or set of vectors disclosed herein.
  • the additional therapeutic agent is at least one of: Rituximab, Cetuximab, Alemtuzumab (CD52), Atezolizumab (PD-L1), Avelumab (PD-L1), Bevacizumab (VEGF), Brentuximab (CD30), Daratumumab (CD38), Denosumab (RANKL), Dinutuximab (GD2), Elotuzumab (SLAMF7), Ibritumomab (CD20), Ipilimumab (CTLA-4), Necitumumab (EGFR), Nivolumab (PD-1), Obinutuzumab (CD20), Ofatumumab (CD20), Olaratumab (PDGFRa), Panitumumab (EGFR), Pembrolizumab (PD-1), Pertuzumab (HER2),
  • a multispecific antibody “comprising a diabody” includes a multispecific antibody “consisting of a diabody” and a multispecific antibody “consisting essentially of a diabody.”
  • the heavy chain from any vertebrate species can be assigned to one of five different classes (or isotypes): IgA, IgD, IgE, IgG, and IgM. These classes are also designated ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ , respectively.
  • the IgG and IgA classes are further divided into subclasses on the basis of differences in sequence and function. Humans express the following subclasses: IgGl, IgG2, IgG3, IgG4, IgAl, and IgA2.
  • an antibody can comprise one or more CDRs of 7E11. In certain aspects, an antibody can comprise all CDRs of 7E11. In certain aspects, an antibody can comprise one or more variable sequences of 7E11. In certain aspects, an antibody can comprise each variable sequence of 7E11. In certain aspects, an antibody can comprise the heavy chain of 7E11. In certain aspects, an antibody can comprise the light chain of 7E11. In certain aspects, an antibody can comprise the heavy chain and the light chain of 7E11. In certain aspects, an antibody is 7E11.
  • the antibodies described in this paragraph are referred to herein as "variants.”
  • such variants are derived from a sequence provided herein, for example, by affinity maturation, site directed mutagenesis, random mutagenesis, or any other method known in the art or described herein.
  • such variants are not derived from a sequence provided herein and may, for example, be isolated de novo according to the methods provided herein for obtaining antibodies.
  • N-linked glycosylation refers to the attachment of a carbohydrate moiety to the side chain of an asparagine residue.
  • the tripeptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain.
  • X is any amino acid except proline
  • DNA encoding the monoclonal antibodies may be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the monoclonal antibodies).
  • the hybridoma cells can serve as a useful source of DNA encoding antibodies with the desired properties.
  • the DNA may be placed into expression vectors, which are then transfected into host cells such as bacteria (e.g., E. coli), yeast (e.g., Saccharomyces or Pichia sp ), COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce antibody, to produce the monoclonal antibodies.
  • bacteria e.g., E. coli
  • yeast e.g., Saccharomyces or Pichia sp
  • COS cells e.g., Chinese hamster ovary (CHO) cells
  • myeloma cells that do not otherwise produce
  • excipients that may be used with the pharmaceutical compositions include, for example, albumin, antioxidants, antibacterial agents, antifungal agents, bioabsorbable polymers, chelating agents, controlled release agents, diluents, dispersing agents, dissolution enhancers, emulsifying agents, gelling agents, ointment bases, penetration enhancers, preservatives, solubilizing agents, solvents, stabilizing agents, sugars, and combinations thereof. Specific examples of each of these agents are described, for example, in the
  • anhydrous pharmaceutical composition should be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions can be packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e.g. , vials), blister packs, and strip packs.
  • a dose of an antibody or composition provided herein can be administered to achieve a steady-state concentration of the antibody in blood or serum of the subject.
  • the steady-state concentration can be determined by measurement according to techniques available to those of skill or can be based on the physical characteristics of the subject such as height, weight and age.
  • any cancer where the cancer cells express CD47 (e.g., in some cases, the cancer cells exhibit increased expression of CD47 compared to non-cancer cells), is a suitable cancer to be treated by the subject methods and compositions (e.g., a subject anti-SIRPa antibody).
  • Carcinomas are malignancies that originate in the epithelial tissues. Epithelial cells cover the external surface of the body, line the internal cavities, and form the lining of glandular tissues. Examples of carcinomas include, but are not limited to: adenocarcinoma (cancer that begins in glandular (secretory) cells), e.g., cancers of the breast, pancreas, lung, prostate, and colon can be adenocarcinomas; adrenocortical carcinoma; hepatocellular carcinoma; renal cell carcinoma; ovarian carcinoma; carcinoma in situ; ductal carcinoma; carcinoma of the breast; basal cell carcinoma; squamous cell carcinoma; transitional cell carcinoma; colon carcinoma; nasopharyngeal carcinoma; multilocular cystic renal cell carcinoma; oat cell carcinoma; large cell lung carcinoma; small cell lung carcinoma; non- small cell lung carcinoma; and the like. Carcinomas may be found in prostrate, pancreas, colon, brain (usually as secondary metastases), lung, breast
  • GIST gastrointestinal stromal tumor
  • hemangiopericytoma hemangiosarcoma (more commonly referred to as "angiosarcoma”); kaposi's sarcoma; leiomyosarcoma; liposarcoma; lymphangiosarcoma; malignant peripheral nerve sheath tumor (MPNST); neurofibrosarcoma; synovial sarcoma; undifferentiated pleomorphic sarcoma, and the like).
  • Melanoma is a form of cancer that begins in melanocytes (cells that make the pigment melanin). It may begin in a mole (skin melanoma), but can also begin in other pigmented tissues, such as in the eye or in the intestines.
  • NHL non-Hodgkin lymphomas
  • EGFR epidermal growth factor receptor
  • ERBB1 epidermal growth factor receptor 1
  • ERBB2 also known as HER2
  • ERBB3 MET
  • IGF 1R insulin-like growth factor 1 receptor
  • EPHA3 ephrin receptor A3
  • TNF tumor necrosis factor-related apoptosis-inducing ligand receptor 1
  • TRAILR1 tumor necrosis factor-related apoptosis-inducing ligand receptor 1
  • TNFRSF10A TNFRSF10A
  • TRAILR2 also known as TNFRSF10B
  • RNFSF l receptor activator of nuclear factor- ⁇ ligand
  • Antigens involved in angiogenesis are usually proteins or growth factors that support the formation of new microvasculature, including vascular endothelial growth factor (VEGF), VEGF receptor (VEGFR), integrin ⁇ 3 and integrin ⁇ 5 ⁇ 1.
  • VEGF vascular endothelial growth factor
  • VEGFR VEGF receptor
  • integrin ⁇ 3 integrin ⁇ 5 ⁇ 1.
  • Tumor stroma and the extracellular matrix are indispensable support structures for a tumor.
  • Stromal and extracellular matrix antigens that are therapeutic targets include fibroblast activation protein (FAP) and tenascin.
  • FAP fibroblast activation protein
  • tenascin tenascin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
PCT/US2018/043699 2017-07-26 2018-07-25 ANTI-SIRP-ALPHA ANTIBODIES AND ASSOCIATED METHODS Ceased WO2019023347A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
SG11202000658PA SG11202000658PA (en) 2017-07-26 2018-07-25 Anti-sirp-alpha antibodies and related methods
KR1020207005520A KR102670957B1 (ko) 2017-07-26 2018-07-25 항-sirp-알파 항체 및 관련 방법
JP2020504234A JP7122370B2 (ja) 2017-07-26 2018-07-25 抗ｓｉｒｐ－アルファ抗体及び関連方法
MX2020000957A MX2020000957A (es) 2017-07-26 2018-07-25 Anticuerpos anti-sirp-alfa y metodos relacionados.
AU2018308364A AU2018308364C1 (en) 2017-07-26 2018-07-25 Anti-SIRP-alpha antibodies and related methods
BR112020001653-5A BR112020001653A2 (pt) 2017-07-26 2018-07-25 anticorpos anti-sirp-alfa e métodos relacionados
CN201880060680.2A CN111448210B (zh) 2017-07-26 2018-07-25 抗SIRP-α抗体及相关方法
PL18765224.3T PL3658589T3 (pl) 2017-07-26 2018-07-25 Przeciwciała anty-sirp-alfa i powiązane sposoby
EP18765224.3A EP3658589B1 (en) 2017-07-26 2018-07-25 Anti-sirp-alpha antibodies and related methods
CA3071193A CA3071193A1 (en) 2017-07-26 2018-07-25 Anti-sirp-alpha antibodies and related methods
ES18765224T ES2963157T3 (es) 2017-07-26 2018-07-25 Anticuerpos anti-SIRP-alfa y métodos relacionados
IL272218A IL272218A (en) 2017-07-26 2020-01-23 ANTI-SIRP-ALPHA ANTIBODIES AND RELATED METHODS
JP2022078181A JP7383074B2 (ja) 2017-07-26 2022-05-11 抗ｓｉｒｐ－アルファ抗体及び関連方法
AU2022204618A AU2022204618B2 (en) 2017-07-26 2022-06-29 Anti-SIRP-alpha antibodies and related methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762537207P 2017-07-26 2017-07-26
US62/537,207 2017-07-26

Publications (1)

Publication Number Publication Date
WO2019023347A1 true WO2019023347A1 (en) 2019-01-31

Family

ID=63490671

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/043699 Ceased WO2019023347A1 (en) 2017-07-26 2018-07-25 ANTI-SIRP-ALPHA ANTIBODIES AND ASSOCIATED METHODS

Country Status (14)

Country Link
US (2) US10961318B2 (enExample)
EP (1) EP3658589B1 (enExample)
JP (2) JP7122370B2 (enExample)
KR (1) KR102670957B1 (enExample)
CN (1) CN111448210B (enExample)
AU (2) AU2018308364C1 (enExample)
BR (1) BR112020001653A2 (enExample)
CA (1) CA3071193A1 (enExample)
ES (1) ES2963157T3 (enExample)
IL (1) IL272218A (enExample)
MX (1) MX2020000957A (enExample)
PL (1) PL3658589T3 (enExample)
SG (1) SG11202000658PA (enExample)
WO (1) WO2019023347A1 (enExample)

Cited By (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10851164B2 (en) 2017-04-13 2020-12-01 Aduro Biotech Holdings, Europe B.V. Anti-SIRPα antibodies
WO2020242895A1 (en) * 2019-05-24 2020-12-03 Forty Seven, Inc. Regimes for co-administration of immunotherapeutic agents against c-kit and cd47
WO2020247820A1 (en) 2019-06-07 2020-12-10 ALX Oncology Inc. Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
WO2020263830A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
US10927173B2 (en) 2016-01-11 2021-02-23 Forty Seven, Inc. Humanized, mouse or chimeric anti-CD47 monoclonal antibodies
US10961318B2 (en) 2017-07-26 2021-03-30 Forty Seven, Inc. Anti-SIRP-α antibodies and related methods
WO2021076908A1 (en) 2019-10-18 2021-04-22 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
WO2021087064A1 (en) 2019-10-31 2021-05-06 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
WO2021108693A1 (en) 2019-11-27 2021-06-03 ALX Oncology Inc. Combination therapies for treating cancer
US20210171593A1 (en) * 2018-04-17 2021-06-10 Hangzhou Sumgen Biotech Co., Ltd. Fusion protein binding to cd47 protein and application thereof
US11041022B2 (en) 2018-11-26 2021-06-22 Forty Seven, Inc. Humanized antibodies against c-Kit
WO2021130638A1 (en) 2019-12-24 2021-07-01 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
WO2021163064A2 (en) 2020-02-14 2021-08-19 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
WO2021236658A1 (en) 2020-05-19 2021-11-25 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
WO2021247430A1 (en) 2020-06-01 2021-12-09 ALX Oncology Inc. Combination therapies comprising a hypomethylation agent for treating cancer
CN114040925A (zh) * 2019-12-24 2022-02-11 礼新医药科技(上海)有限公司 抗SIRPα单克隆抗体及其用途
WO2022087149A2 (en) 2020-10-22 2022-04-28 Gilead Sciences, Inc. Interleukin-2-fc fusion proteins and methods of use
US11319373B2 (en) 2018-05-25 2022-05-03 Alector Llc Anti-SIRPA antibodies and methods of use thereof
WO2022098642A1 (en) 2020-11-03 2022-05-12 Rdiscovery, LLC Therapies for treatment of cancer and phagocytosis-deficiency related diseases
WO2022120286A1 (en) 2020-12-06 2022-06-09 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
WO2022221304A1 (en) 2021-04-14 2022-10-20 Gilead Sciences, Inc. CO-INHIBITION OF CD47/SIRPα BINDING AND NEDD8-ACTIVATING ENZYME E1 REGULATORY SUBUNIT FOR THE TREATMENT OF CANCER
WO2022241157A1 (en) 2021-05-13 2022-11-17 ALX Oncology Inc. Combination therapies for treating cancer
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
WO2022254379A1 (en) 2021-06-04 2022-12-08 Boehringer Ingelheim International Gmbh Anti-sirp-alpha antibodies
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023278377A1 (en) 2021-06-29 2023-01-05 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
WO2023012350A1 (en) 2021-08-05 2023-02-09 Immunos Therapeutics Ag Combination medicaments comprising hla fusion proteins
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
WO2023077030A1 (en) 2021-10-29 2023-05-04 Gilead Sciences, Inc. Cd73 compounds
WO2023076983A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023122581A2 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023147418A1 (en) 2022-01-28 2023-08-03 Gilead Sciences, Inc. Parp7 inhibitors
EP4003375A4 (en) * 2019-07-31 2023-09-06 Forty Seven, Inc. DEPLETION DIETS FOR MODIFIED T CELL OR NK CELL THERAPY
EP4245756A1 (en) 2022-03-17 2023-09-20 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023183817A1 (en) 2022-03-24 2023-09-28 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
US11779642B2 (en) 2016-12-09 2023-10-10 Alector Llc Anti-SIRP-alpha antibodies and methods of use thereof
WO2023196784A1 (en) 2022-04-05 2023-10-12 Gilead Sciences, Inc. Combinations of antibody therapies for treating colorectal cancer
WO2023205719A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023235754A1 (en) 2022-06-01 2023-12-07 ALX Oncology Inc. Combination therapies for treating urothelial carcinoma
WO2024003353A1 (en) 2022-07-01 2024-01-04 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
US11891450B2 (en) 2018-02-12 2024-02-06 Forty Seven, Inc. Anti-CD47 agent-based treatment of CD20-positive cancer
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024105180A1 (en) 2022-11-16 2024-05-23 Boehringer Ingelheim International Gmbh Predictive efficacy biomarkers for anti-sirpa antibodies
WO2024137852A1 (en) 2022-12-22 2024-06-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024165671A1 (en) 2023-02-08 2024-08-15 Immunos Therapeutics Ag FUSION PROTEINS OF ß2 MICROGLOBULIN, HLA HEAVY CHAIN POLYPEPTIDES, AND INHIBITOR OF CD47-SIRPA
US12084499B2 (en) 2018-09-27 2024-09-10 Celgene Corporation SIRP-α binding proteins and methods of use thereof
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
EP4261223A4 (en) * 2020-12-11 2024-11-13 BioRay Pharmaceutical Co., Ltd. ANTI-SIRP? ANTIBODIES AND THEIR APPLICATION
EP4253416A4 (en) * 2020-11-30 2024-11-13 Qure Biotechnology (Shanghai) Co., Ltd. ANTI-SIRPALPHA ANTIBODY OR ASSOCIATED ANTIGEN-BINDING FRAGMENT, AND USE THEREOF
US12180295B2 (en) 2018-11-15 2024-12-31 Byondis B.V. Humanized anti-SIRPα antibodies
WO2025006720A1 (en) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Kras modulating compounds
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
WO2025024663A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
US12252546B2 (en) 2016-04-14 2025-03-18 Ose Immunotherapeutics Anti-SIRPa antibodies and their therapeutic applications
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025202222A1 (en) 2024-03-25 2025-10-02 Institut National de la Santé et de la Recherche Médicale Therapeutic use of sting and tlrs agonists to induce p16 expression in immune cells
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
PE20201265A1 (es) 2018-03-21 2020-11-19 Alx Oncology Inc Anticuerpos contra proteina alfa reguladora de senal y metodos de uso
US12133884B2 (en) 2018-05-11 2024-11-05 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
EP3876977A1 (en) 2018-11-06 2021-09-15 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
US11013764B2 (en) 2019-04-30 2021-05-25 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
AU2020286285A1 (en) * 2019-08-20 2021-03-11 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-SIRPa antibodies
KR20220097875A (ko) 2019-09-03 2022-07-08 마이얼로이드 테라퓨틱스, 인크. 게놈 통합을 위한 방법 및 조성물
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
WO2022048616A1 (zh) * 2020-09-04 2022-03-10 江苏恒瑞医药股份有限公司 SIRPγ变体及其融合蛋白
MX2023005201A (es) 2020-11-04 2023-06-28 Myeloid Therapeutics Inc Composiciones de proteinas de fusion quimerica modificadas por ingenieria y metodos de uso de las mismas.
EP4337268A4 (en) 2021-05-11 2025-06-04 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
WO2023020459A1 (zh) * 2021-08-17 2023-02-23 杭州九源基因工程有限公司 靶向SIRPα的单克隆抗体及其用途
WO2024167830A2 (en) * 2023-02-06 2024-08-15 Apeximmune Therapeutics Inc. ANTI-SIRPα ANTIBODIES AND USES THEREOF

Citations (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
WO1987000195A1 (en) 1985-06-28 1987-01-15 Celltech Limited Animal cell culture
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0453082A1 (en) 1990-03-09 1991-10-23 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5500362A (en) 1987-01-08 1996-03-19 Xoma Corporation Chimeric antibody with specificity to human B cell surface antigen
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5545807A (en) 1988-10-12 1996-08-13 The Babraham Institute Production of antibodies from transgenic animals
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5585089A (en) 1988-12-28 1996-12-17 Protein Design Labs, Inc. Humanized immunoglobulins
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
US5589369A (en) 1992-02-11 1996-12-31 Cell Genesys Inc. Cells homozygous for disrupted target loci
US5591669A (en) 1988-12-05 1997-01-07 Genpharm International, Inc. Transgenic mice depleted in a mature lymphocytic cell-type
US5624821A (en) 1987-03-18 1997-04-29 Scotgen Biopharmaceuticals Incorporated Antibodies with altered effector functions
WO1997030087A1 (en) 1996-02-16 1997-08-21 Glaxo Group Limited Preparation of glycosylated antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5821337A (en) 1991-06-14 1998-10-13 Genentech, Inc. Immunoglobulin variants
WO1998058964A1 (en) 1997-06-24 1998-12-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
WO1999051642A1 (en) 1998-04-02 1999-10-14 Genentech, Inc. Antibody variants and fragments thereof
WO1999058572A1 (en) 1998-05-08 1999-11-18 Cambridge University Technical Services Limited Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis
WO2000061739A1 (fr) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
WO2001029246A1 (fr) 1999-10-19 2001-04-26 Kyowa Hakko Kogyo Co., Ltd. Procede de production d'un polypeptide
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
WO2002031140A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions
US20020164328A1 (en) 2000-10-06 2002-11-07 Toyohide Shinkawa Process for purifying antibody
WO2003011878A2 (en) 2001-08-03 2003-02-13 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US20030115614A1 (en) 2000-10-06 2003-06-19 Yutaka Kanda Antibody composition-producing cell
US6602684B1 (en) 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
WO2003085107A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cells with modified genome
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
WO2003085119A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
US20030215914A1 (en) 2001-12-10 2003-11-20 Erwin Houtzager Structure for presenting desired peptide sequences
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20040109865A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
US20040110282A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
WO2004056312A2 (en) 2002-12-16 2004-07-08 Genentech, Inc. Immunoglobulin variants and uses thereof
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
US20050014934A1 (en) 2002-10-15 2005-01-20 Hinton Paul R. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005035778A1 (ja) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. α1,6-フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法
WO2005035586A1 (ja) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. 融合蛋白質組成物
US20050123546A1 (en) 2003-11-05 2005-06-09 Glycart Biotechnology Ag Antigen binding molecules with increased Fc receptor binding affinity and effector function
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
WO2006029879A2 (en) 2004-09-17 2006-03-23 F.Hoffmann-La Roche Ag Anti-ox40l antibodies
WO2006044908A2 (en) 2004-10-20 2006-04-27 Genentech, Inc. Antibody formulation in histidine-acetate buffer
WO2007055916A2 (en) 2005-11-07 2007-05-18 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
WO2007117505A2 (en) 2006-04-05 2007-10-18 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20080069820A1 (en) 2006-08-30 2008-03-20 Genentech, Inc. Multispecific antibodies
US7371826B2 (en) 1999-01-15 2008-05-13 Genentech, Inc. Polypeptide variants with altered effector function
WO2008077546A1 (en) 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
US7521056B2 (en) 2005-04-06 2009-04-21 Ibc Pharmaceuticals, Inc. Stably tethered structures of defined compositions with multiple functions or binding specificities
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US7550143B2 (en) 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20100266505A1 (en) 2007-10-17 2010-10-21 Wyeth Llc Immunotherapy regimes dependent on apoe status
WO2011066501A1 (en) * 2009-11-30 2011-06-03 Centocor Ortho Biotech Inc. Antibody fc mutants with ablated effector functions
US8258082B2 (en) 2000-12-18 2012-09-04 Dyax Corp. Focused libraries of genetic packages
CN103665165A (zh) 2013-08-28 2014-03-26 江苏匡亚生物医药科技有限公司 一种靶向人CD47-SIRPα信号通路的双特异性抗体及其制备方法和用途
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US20140242095A1 (en) 2011-10-19 2014-08-28 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
WO2015103072A1 (en) 2013-12-30 2015-07-09 Epimab Biotherapeutics Fabs-in-tandem immunoglobulin and uses thereof
WO2015138600A2 (en) 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
US9150641B2 (en) 2009-12-22 2015-10-06 Hoffmann—La Roche Inc. Sequence dependent aggregation
WO2017068164A1 (en) * 2015-10-21 2017-04-27 Ose Immunotherapeutics Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2259122A1 (en) 1996-06-17 1997-12-24 Max Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. Novel ptp-20, pcp-2, bdp1, clk and sirp proteins and related products and methods
CA2226962A1 (en) 1998-02-16 1999-08-16 Marie Sarfati Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection
AU1224200A (en) 1998-10-23 2000-05-15 Agnes Vignery Methods for modulating cell fusion
EP1048299A1 (en) 1999-04-28 2000-11-02 Faculteit der Geneeskunde van de Vrije Universiteit Method for inhibiting cell functioning for use in anti-inflammatory and anti-tumour therapies
AU1701001A (en) 1999-11-30 2001-06-12 Eberhard-Karls-Universitat Tubingen Universitatsklinikum Antibodies against signal regulator proteins
GB9930706D0 (en) 1999-12-24 2000-02-16 Medical Res Council Composition for inhibiting macrophage activity
GB0021484D0 (en) 2000-09-01 2000-10-18 Boehringer Ingelheim Pharma Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
US20020155511A1 (en) 2000-09-08 2002-10-24 Carolyn Horrocks Novel antibody compositions for the negative selection of specific rat leukocyte subsets
GB0124145D0 (en) 2001-10-08 2001-11-28 Bayer Ag Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
JP2006515165A (ja) 2002-09-16 2006-05-25 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
US8613922B2 (en) 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
US20040213792A1 (en) 2003-04-24 2004-10-28 Clemmons David R. Method for inhibiting cellular activation by insulin-like growth factor-1
JP3936673B2 (ja) 2003-06-02 2007-06-27 国立大学法人群馬大学 Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体
CN101970478A (zh) 2007-10-11 2011-02-09 大学健康网络 调节SIRPα-CD47相互作用以增加造血干细胞植入以及用于此的化合物
PT3056515T (pt) 2008-01-15 2019-07-19 Univ Leland Stanford Junior Métodos para manipulação da fagocitose mediada por cd47
PT4160212T (pt) 2008-01-15 2024-06-25 Univ Leland Stanford Junior Marcadores de células estaminais de leucemia mielóide aguda
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
CA2747678A1 (en) 2008-12-19 2010-06-24 Novartis Ag Soluble polypeptides for use in treating autoimmune and inflammatory disorders
PL2429574T3 (pl) 2009-05-15 2015-12-31 Univ Health Network Kompozycje i sposoby leczenia nowotworów hematologicznych celujące w oddziaływanie SIRP-CD47
AU2010334974A1 (en) 2009-12-22 2012-07-12 Novartis Ag Tetravalent CD47-antibody constant region fusion protein for use in therapy
CN103189502A (zh) 2010-08-27 2013-07-03 大学健康网络 基于sirpa表达富集源自多能干细胞的心肌祖细胞和心肌细胞的方法
WO2012162741A1 (en) 2011-06-01 2012-12-06 Monash University Enrichment of cardiomyocytes
PL4119153T3 (pl) 2013-02-05 2024-09-02 The Board Of Trustees Of The Leland Stanford Junior University Terapie ukierunkowane na cd47 w leczeniu choroby zakaźnej
WO2014179132A1 (en) 2013-04-29 2014-11-06 The Board Of Trustees Of The Leland Stanford Junior University Use of anti-cd47 agents to enhance immunization
US10329354B2 (en) 2013-09-18 2019-06-25 The Board Of Trustees Of The Leland Stanford Junior University Modulation of efferocytosis pathways for treatment of atherosclerotic disease
WO2015172037A1 (en) 2014-05-09 2015-11-12 Becton, Dickinson And Company Cell surface signature for processing cardiomyocyte subsets from heterogeneous cell samples
CN107209187B (zh) 2014-07-11 2021-04-20 国立健康与医学研究所 用于诊断血液癌症的方法
WO2016205042A1 (en) 2015-06-16 2016-12-22 The Board Of Trustees Of The Leland Stanford Junior University SIRPα AGONIST ANTIBODY
EA038880B1 (ru) 2016-01-11 2021-11-01 Форти Севен, Инк. Гуманизированные моноклональные антитела, моноклональные антитела мыши или химерные моноклональные антитела против cd47
DK3443010T3 (da) * 2016-04-14 2024-09-30 Ose Immunotherapeutics Nye anti-SIRPa-antistoffer og terapeutiske anvendelser deraf
CN109862910A (zh) 2016-08-03 2019-06-07 小利兰·斯坦福大学托管委员会 破坏巨噬细胞上的Fc受体接合增强抗SIRPα抗体疗法的功效
ES2963157T3 (es) 2017-07-26 2024-03-25 Forty Seven Inc Anticuerpos anti-SIRP-alfa y métodos relacionados

Patent Citations (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
WO1987000195A1 (en) 1985-06-28 1987-01-15 Celltech Limited Animal cell culture
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5500362A (en) 1987-01-08 1996-03-19 Xoma Corporation Chimeric antibody with specificity to human B cell surface antigen
US5624821A (en) 1987-03-18 1997-04-29 Scotgen Biopharmaceuticals Incorporated Antibodies with altered effector functions
US5648260A (en) 1987-03-18 1997-07-15 Scotgen Biopharmaceuticals Incorporated DNA encoding antibodies with altered effector functions
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US5545807A (en) 1988-10-12 1996-08-13 The Babraham Institute Production of antibodies from transgenic animals
US5591669A (en) 1988-12-05 1997-01-07 Genpharm International, Inc. Transgenic mice depleted in a mature lymphocytic cell-type
US5585089A (en) 1988-12-28 1996-12-17 Protein Design Labs, Inc. Humanized immunoglobulins
US6180370B1 (en) 1988-12-28 2001-01-30 Protein Design Labs, Inc. Humanized immunoglobulins and methods of making the same
US5693762A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Humanized immunoglobulins
US5693761A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Polynucleotides encoding improved humanized immunoglobulins
EP0453082A1 (en) 1990-03-09 1991-10-23 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5821337A (en) 1991-06-14 1998-10-13 Genentech, Inc. Immunoglobulin variants
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
US5589369A (en) 1992-02-11 1996-12-31 Cell Genesys Inc. Cells homozygous for disrupted target loci
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
WO1997030087A1 (en) 1996-02-16 1997-08-21 Glaxo Group Limited Preparation of glycosylated antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO1998058964A1 (en) 1997-06-24 1998-12-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
WO1999051642A1 (en) 1998-04-02 1999-10-14 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6602684B1 (en) 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
WO1999058572A1 (en) 1998-05-08 1999-11-18 Cambridge University Technical Services Limited Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis
US7371826B2 (en) 1999-01-15 2008-05-13 Genentech, Inc. Polypeptide variants with altered effector function
US7332581B2 (en) 1999-01-15 2008-02-19 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2000061739A1 (fr) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
WO2001029246A1 (fr) 1999-10-19 2001-04-26 Kyowa Hakko Kogyo Co., Ltd. Procede de production d'un polypeptide
US20020164328A1 (en) 2000-10-06 2002-11-07 Toyohide Shinkawa Process for purifying antibody
WO2002031140A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions
US20030115614A1 (en) 2000-10-06 2003-06-19 Yutaka Kanda Antibody composition-producing cell
US8258082B2 (en) 2000-12-18 2012-09-04 Dyax Corp. Focused libraries of genetic packages
WO2003011878A2 (en) 2001-08-03 2003-02-13 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20030215914A1 (en) 2001-12-10 2003-11-20 Erwin Houtzager Structure for presenting desired peptide sequences
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20040109865A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
US20040110282A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
WO2003085119A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
WO2003085107A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cells with modified genome
US20050014934A1 (en) 2002-10-15 2005-01-20 Hinton Paul R. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004056312A2 (en) 2002-12-16 2004-07-08 Genentech, Inc. Immunoglobulin variants and uses thereof
WO2005035586A1 (ja) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. 融合蛋白質組成物
WO2005035778A1 (ja) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. α1,6-フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法
US20050123546A1 (en) 2003-11-05 2005-06-09 Glycart Biotechnology Ag Antigen binding molecules with increased Fc receptor binding affinity and effector function
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
WO2006029879A2 (en) 2004-09-17 2006-03-23 F.Hoffmann-La Roche Ag Anti-ox40l antibodies
WO2006044908A2 (en) 2004-10-20 2006-04-27 Genentech, Inc. Antibody formulation in histidine-acetate buffer
US7550143B2 (en) 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US7521056B2 (en) 2005-04-06 2009-04-21 Ibc Pharmaceuticals, Inc. Stably tethered structures of defined compositions with multiple functions or binding specificities
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
WO2007055916A2 (en) 2005-11-07 2007-05-18 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
WO2007117505A2 (en) 2006-04-05 2007-10-18 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20080069820A1 (en) 2006-08-30 2008-03-20 Genentech, Inc. Multispecific antibodies
WO2008077546A1 (en) 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US20100266505A1 (en) 2007-10-17 2010-10-21 Wyeth Llc Immunotherapy regimes dependent on apoe status
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2011066501A1 (en) * 2009-11-30 2011-06-03 Centocor Ortho Biotech Inc. Antibody fc mutants with ablated effector functions
US9150641B2 (en) 2009-12-22 2015-10-06 Hoffmann—La Roche Inc. Sequence dependent aggregation
US20140242095A1 (en) 2011-10-19 2014-08-28 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
CN103665165A (zh) 2013-08-28 2014-03-26 江苏匡亚生物医药科技有限公司 一种靶向人CD47-SIRPα信号通路的双特异性抗体及其制备方法和用途
WO2015103072A1 (en) 2013-12-30 2015-07-09 Epimab Biotherapeutics Fabs-in-tandem immunoglobulin and uses thereof
WO2015138600A2 (en) 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
WO2017068164A1 (en) * 2015-10-21 2017-04-27 Ose Immunotherapeutics Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer

Non-Patent Citations (145)

* Cited by examiner, † Cited by third party
Title
"Genbank", Database accession no. AAH26692.1
"Genbank", Database accession no. BAA12974.1
"Genbank", Database accession no. EAX10606.1
"Genbank", Database accession no. EAX10609.1
"Genbank", Database accession no. EAX10611.1
"Genbank", Database accession no. NP_542970.1
"Genbank", Database accession no. XP_005260726.1
"Genbank", Database accession no. XP_011527475.1
"Handbook of Pharmaceutical Excipients", 2009
"Handbook of Pharmaceutical Excipients", 2009, THE PHARMACEUTICAL PRESS
"Methods In Enzymology", ACADEMIC PRESS, INC.
"Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells", NATURE IMMUNOLOGY, vol. 8, 2007, pages 1313
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING COMPANY
"Sirpa modulates engraftment of human hematopoietic stem cells", NATURE IMMUNOLOGY, vol. 8, 2007, pages 1313
"The Pharmacology of Monoclonal Antibodies", vol. 113, SPRINGER-VERLAG, pages: 269 - 315
A.L. LEHNINGER: "Biochemistry", WORTH PUBLISHERS, INC.
AALBERSE ET AL., IMMUNOLOGY, vol. 105, 2002, pages 9 - 19
ABHINANDAN; MARTIN, IMMUNOLOGY, vol. 45, 2008, pages 3832 - 3839
AL-LAZIKANI ET AL., J. MOL. BIOL., vol. 273, 1997, pages 927 - 948
ANALYTICAL BIOCHEMISTRY, vol. 348, 2006, pages 24 - 39
ARABI GHAHROUDI ET AL., FEBSLETTERS, vol. 414, 1998, pages 521 - 526
ARMOUR ET AL., EUR J IMMUNOL., vol. 29, no. 8, 1999, pages 2613 - 24
ARMOUR ET AL., EUR. J. IMMUNOL., vol. 29, 1999, pages 2613 - 2624
ARMOUR ET AL., MOL. IMMUNOL., vol. 40, 2003, pages 585 - 593
ARMOUR KL. ET AL., EUR J IMMUNOL., vol. 29, no. 8, 1999, pages 2613 - 24
BARNES ET AL., ANAL. BIOCHEM., vol. 102, 1980, pages 255
BINZ ET AL., NAT. BIOTECHNOL., vol. 23, 2005, pages 1257 - 1268
BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81 - 83
BRUGGEMANN ET AL., J. EXP. MED., vol. 166, 1987, pages 1351 - 1361
BRUGGERMANN ET AL., YEAR IN IMMUNO., vol. 7, 1993, pages 33
CANFIELD; MORRISON, J. EXP. MED., vol. 173, 1991, pages 1483
CAREY; SUNDBERG: "Advanced Organic Chemistry", 1992, PLENUM PRESS
CARLRING ET AL., PLOS ONE, vol. 6, 2011, pages e22533
CARTER ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 163 - 167
CLYNES ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 95, 1998, pages 652 - 656
COLOMA; MORRISON, NATURE BIOTECHNOL., vol. 15, 1997, pages 159 - 163
COX ET AL.: "Immunoassay Methods", ASSAY GUIDANCE MANUAL [INTERNET), 24 December 2014 (2014-12-24), Retrieved from the Internet <URL:www.ncbi.nlm.nih.gov/books/NBK92434>
CRAGG ET AL., BLOOD, vol. 101, 2003, pages 1045 - 1052
CRAGG ET AL., BLOOD, vol. 103, 2004, pages 2738 - 2743
CREIGHTON: "Proteins: Structures and Molecular Properties", 1993, W. H. FREEMAN & CO.
DOPPALAPUDI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 107, 2010, pages 22611 - 22616
DUNCAN ET AL., NATURE, vol. 332, 1988, pages 563
DUNCAN; WINTER, NATURE, vol. 322, 1988, pages 738 - 740
EBERSBACH ET AL., J. MOL. BIOL., vol. 372, 2007, pages 172 - 185
EMANUEL ET AL., MABS, vol. 3, 2011, pages 38 - 48
FERNANDEZ, CURR. OPINION IN BIOTECH., vol. 15, 2004, pages 364 - 373
FINCO ET AL., J. PHARM. BIOMED. ANAL., vol. 54, 2011, pages 351 - 358
GAZZANO-SANTORO ET AL., J. IMMUNOL. METHODS, vol. 202, 1996, pages 163 - 171
GEYER; BRENT, METH. ENZYMOL., vol. 328, 2000, pages 171 - 208
GODING J.W.: "Monoclonal Antibodies: Principles and Practice", 1986, ACADEMIC PRESS
GRAMER ET AL., MABS, vol. 5, 2013, pages 962 - 972
GRAVERSEN ET AL., J. BIOL. CHEM., vol. 275, 2000, pages 37390 - 37396
GRUBER ET AL., J. IMMUNOL., vol. 152, 1994, pages 5368 - 5374
GUSS ET AL., EMBO J., vol. 5, 1986, pages 1567 - 1575
HAM ET AL., METH. ENZ., vol. 58, 1979, pages 44
HAMILTON ET AL., SCIENCE, vol. 313, 2006, pages 1441
HARLOW; LANE: "Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY
HATHERLEY ET AL., J.B.C., vol. 282, 2007, pages 14567 - 75
HELLSTROM ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 82, 1985, pages 1499 - 1502
HELLSTROM ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 83, 1986, pages 7059 - 7063
HEZAREH M ET AL: "Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 75, no. 24, 1 December 2001 (2001-12-01), pages 12161 - 12168, XP002339184, ISSN: 0022-538X, DOI: 10.1128/JVI.75.24.12161-12168.2001 *
HINTON ET AL., J. IMMUNOL., vol. 176, 2006, pages 346 - 356
HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448
HONEGGE; PLIICKTHUN, J. MOL. BIOL., vol. 309, 2001, pages 657 - 70
HOOGENBOOM ET AL., J. MOL. BIOL., vol. 227, 1991, pages 381 - 388
HOOGENBOOM ET AL., METHODS IN MOLECULAR BIOLOGY, vol. 178, 2001, pages 1 - 37
HUDSON ET AL., NAT. MED., vol. 9, 2003, pages 129 - 134
IDUSOGIE ET AL., J. IMMUNOL., vol. 164, 2000, pages 4178 - 4184
IMAI-NISHIYA ET AL., BMC BIOTECHNOLOGY, vol. 7, 2007, pages 84
JAKOBOVITS ET AL., NATURE, vol. 362, 1993, pages 255 - 258
JAKOBOVITS ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 90, 1993, pages 2551
JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 97, 2008, pages 2426 - 2447
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH
KANDA ET AL., BIOTECHNOL. BIOENG., vol. 94, 2006, pages 680 - 688
KANDA ET AL., J. BIOTECHNOLOGY, vol. 130, 2007, pages 300
KANEKO ET AL., SCIENCE, vol. 313, 2006, pages 760
KIPRIYANOV ET AL., J. MOL. BIOL., vol. 293, 1999, pages 41 - 56
KITAGAWA ET AL., J. BIOL. CHEM., vol. 269, no. 27, 1994, pages 17872
KODJO AYI ET AL: "CD47-SIRP[alpha] Interactions Regulate Macrophage Uptake of Plasmodium falciparum-Infected Erythrocytes and Clearance of Malaria In Vivo", INFECTION AND IMMUNITY, vol. 84, no. 7, 1 July 2016 (2016-07-01), pages 2002 - 2011, XP055522887, ISSN: 0019-9567, DOI: 10.1128/IAI.01426-15 *
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495 - 497
KOSTELNY ET AL., J. IMMUNOL., vol. 148, 1992, pages 1547 - 1553
KOZBOR, J. IMMUNOL., vol. 133, 1984, pages 3001
LABRIJN ET AL., NATURE PROTOCOLS, vol. 9, 2014, pages 2450 - 2463
LABRIJN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 110, 2013, pages 5145 - 5150
LAFLEUR ET AL., MABS, vol. 5, 2013, pages 208 - 218
LAZAR ET AL., PROC. NATL. ACAD. SCI. USA, vol. 103, 2006, pages 4005 - 4010
LEE ET AL., J. IMMUNOL., vol. 179, 2007, pages 7741 - 7750
LEE ET AL., J. IMMUNOL., vol. 179, no. 11, 2007, pages 7741 - 7750
LEE ET AL., J.B.C., vol. 285, 2010, pages 37953 - 63
LEFRANC ET AL., DEV. COMP. IMMUNOL., vol. 27, 2003, pages 55 - 77
LI ET AL., J. AUTOIMMUNITY, vol. 21, 2003, pages 83 - 92
LINDMARK ET AL., J. IMMUNOL. METH., vol. 62, 1983, pages 1 - 13
MACCALLUM ET AL., J. MOL. BIOL., vol. 262, 1996, pages 732 - 745
MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597
MERCHANT ET AL., NATURE BIOTECHNOL., vol. 16, 1998, pages 677 - 681
MILER ET AL., J. IMMUNOL., vol. 170, 2003, pages 4854 - 4861
MILSTEIN; CUELLO, NATURE, vol. 305, 1983, pages 537 - 540
MOORE ET AL., BLOOD, vol. 117, 2011, pages 454 - 451
MORRIS: "Methods in Molecular Biology", vol. 66, 1996, HUMANA PRESS, article "Epitope Mapping Protocols"
MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855
MUYLDERMANS ET AL., TRENDS IN BIOCHEM. SCI., vol. 26, 2001, pages 230 - 245
OKAZAKI ET AL., J. MOL. BIOL., vol. 336, 2004, pages 1239 - 1249
PAUL: "Fundamental Immunology", 2013, LIPPINCOTT WILLIAMS & WILKINS
PETKOVA ET AL., INT'L. IMMUNOL., vol. 18, 2006, pages 1759 - 1769
PLIICKTHUN: "The Pharmacology of Monoclonal Antibodies", vol. 113, 1994, SPRINGER-VERLAG, pages: 269 - 315
PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596
QUEEN ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 86, 1989, pages 10029 - 10033
RADER ET AL., PROC. NAT. ACAD. SCI. U.S.A., vol. 95, 1998, pages 8910 - 8915
RAVETCH; KINET, ANNU. REV. IMMUNOL., vol. 9, 1991, pages 457 - 492
RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329
RIPKA ET AL., ARCH. BIOCHEM. BIOPHYS., vol. 249, 1986, pages 533 - 545
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 2012, COLD SPRING HARBOR LABORATORY PRESS
SCHROEDER; CAVACINI, J. ALLERGY CLIN. IMMUNOL., vol. 125, 2010, pages 41 - 52
SEIFFERT M ET AL: "HUMAN SIGNAL-REGULATORY PROTEIN IS EXPRESSED ON NORMAL, BUT NOT ON SUBSETS OF LEUKEMIC MYELOID CELLS AND MEDIATES CELLULAR ADHESION INVOLVING ITS COUNTERRECEPTOR CD47", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 94, no. 11, 1 December 1999 (1999-12-01), pages 3633 - 3643, XP000973562, ISSN: 0006-4971 *
SHIELDS ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 26733 - 26740
SHIELDS RL. ET AL., J BIOL CHEM., vol. 276, no. 9, 2001, pages 6591 - 604
SHOJ-HOSAKA ET AL., J. BIOCHEM., vol. 140, 2006, pages 777
SILACCI ET AL., J. BIOL. CHEM., vol. 289, 2014, pages 14392 - 14398
SILMAN ET AL., CYTOMETRY, vol. 44, 2001, pages 30 - 37
SILVERMAN ET AL., NATURE BIOTECH., vol. 23, 2005, pages 1556 - 1561
SKERRA, CURRENT OPIN. IN BIOTECH., vol. 18, 2007, pages 295 - 304
STAERZ ET AL., NATURE, vol. 314, 1985, pages 628 - 631
STAERZ; BEVAN, PROC. NATL. ACAD. SCI. USA, vol. 83, 1986, pages 1453 - 1457
STEINBERGER ET AL., J. BIOL. CHEM., vol. 275, 2000, pages 36073 - 36078
STROHL ET AL: "Optimization of Fc-mediated effector functions of monoclonal antibodies", CURRENT OPINION IN BIOTECHNOLOGY, LONDON, GB, vol. 20, no. 6, 1 December 2009 (2009-12-01), pages 685 - 691, XP026778879, ISSN: 0958-1669, [retrieved on 20091104], DOI: 10.1016/J.COPBIO.2009.10.011 *
T.E. CREIGHTON: "Proteins: Structures and Molecular Properties", 1993, W.H. FREEMAN AND COMPANY
TADAHIKO YANAGITA ET AL: "Anti-SIRP[alpha] antibodies as a potential new tool for cancer immunotherapy", JCI INSIGHT, vol. 2, no. 1, 12 January 2017 (2017-01-12), pages 1 - 15, XP055421877, ISSN: 2379-3708, DOI: 10.1172/jci.insight.89140 *
TAO ET AL., J. EXP. MED., vol. 178, 1993, pages 661
TODOROVSKA ET AL., J. IMMUNOL. METHODS, vol. 248, 2001, pages 47 - 66
TRAUNECKER ET AL., EMBO J., vol. 10, 1991, pages 3655 - 3659
TUTT ET AL., J. IMMUNOL., vol. 147, 1991, pages 60 - 69
UJITA-LEE ET AL., J. BIOL. CHEM., vol. 264, no. 23, 1989, pages 13848
VOGT; SKERRA, CHEM. BIOCHEM., vol. 5, 2004, pages 191 - 199
WAGNER ET AL., BIOCHEM. & BIOPHYS. RES. COMM., vol. 186, 1992, pages 118 - 1145
WINTER; MILSTEIN, NATURE, vol. 349, 1991, pages 293 - 299
WOZNIAK-KNOPP ET AL., PROTEIN ENG. DES. SEL., vol. 23, 2010, pages 289 - 297
WRIGHT ET AL., TIBTECH, vol. 15, 1997, pages 26 - 32
X. W. ZHAO ET AL: "CD47-signal regulatory protein-alpha (SIRPalpha) interactions form a barrier for antibody-mediated tumor cell destruction", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 108, no. 45, 31 October 2011 (2011-10-31), US, pages 18342 - 18347, XP055232927, ISSN: 0027-8424, DOI: 10.1073/pnas.1106550108 *
YAMANE-OHNUKI ET AL., BIOTECH. BIOENG., vol. 87, 2004, pages 614 - 622
YIN ET AL., MABS, vol. 4, 2012, pages 217 - 225
ZAHND ET AL., J. MOL. BIOL., vol. 369, 2007, pages 1015 - 1028
ZHAO XW ET AL.: "JIANGSU KUANGYA BIOLOGICAL MEDICAL SCIENCE & TECHNOLOGY", PROC NATL ACAD SCI USA, vol. 108, 2011, pages 18342 - 7
ZHUKOVSKY ET AL., BLOOD, vol. 122, 2013, pages 5116

Cited By (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11643461B2 (en) 2016-01-11 2023-05-09 Forty Seven, Inc. Humanized, mouse or chimeric anti-CD47 monoclonal antibodies
US10927173B2 (en) 2016-01-11 2021-02-23 Forty Seven, Inc. Humanized, mouse or chimeric anti-CD47 monoclonal antibodies
US12060423B2 (en) 2016-01-11 2024-08-13 Forty Seven, Inc. Humanized, mouse or chimeric anti-CD47 monoclonal antibodies
US12252546B2 (en) 2016-04-14 2025-03-18 Ose Immunotherapeutics Anti-SIRPa antibodies and their therapeutic applications
US11779642B2 (en) 2016-12-09 2023-10-10 Alector Llc Anti-SIRP-alpha antibodies and methods of use thereof
US12226482B2 (en) 2016-12-09 2025-02-18 Alector Llc Anti-SIRP-alpha antibodies and methods of use thereof
US10851164B2 (en) 2017-04-13 2020-12-01 Aduro Biotech Holdings, Europe B.V. Anti-SIRPα antibodies
US10961318B2 (en) 2017-07-26 2021-03-30 Forty Seven, Inc. Anti-SIRP-α antibodies and related methods
US11753480B2 (en) 2017-07-26 2023-09-12 Forty Seven, Inc. Anti-SIRP-alpha antibodies and related methods
US11891450B2 (en) 2018-02-12 2024-02-06 Forty Seven, Inc. Anti-CD47 agent-based treatment of CD20-positive cancer
US20210171593A1 (en) * 2018-04-17 2021-06-10 Hangzhou Sumgen Biotech Co., Ltd. Fusion protein binding to cd47 protein and application thereof
US11891423B2 (en) * 2018-04-17 2024-02-06 Hangzhou Sumgen Biotech Co., Ltd. Fusion protein binding to CD47 protein and application thereof
US12258410B2 (en) 2018-05-25 2025-03-25 Alector Llc Anti-SIRPα antibodies and methods of use thereof
US11976119B2 (en) 2018-05-25 2024-05-07 Alector Llc Anti-SIRPa antibodies and methods of use thereof
US11319373B2 (en) 2018-05-25 2022-05-03 Alector Llc Anti-SIRPA antibodies and methods of use thereof
US12084499B2 (en) 2018-09-27 2024-09-10 Celgene Corporation SIRP-α binding proteins and methods of use thereof
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
US12180295B2 (en) 2018-11-15 2024-12-31 Byondis B.V. Humanized anti-SIRPα antibodies
US11041022B2 (en) 2018-11-26 2021-06-22 Forty Seven, Inc. Humanized antibodies against c-Kit
US11208482B2 (en) 2018-11-26 2021-12-28 Forty Seven, Inc. Humanized antibodies against c-Kit
US12091458B2 (en) 2018-11-26 2024-09-17 Forty Seven, Inc. Humanized antibodies against c-Kit
CN113906049A (zh) * 2019-05-24 2022-01-07 四十七公司 用于共施用针对c-kit和CD47的免疫治疗剂的方案
JP2022533253A (ja) * 2019-05-24 2022-07-21 フォーティ セブン， インコーポレイテッド ｃ－ｋｉｔ及びＣＤ４７に対する免疫療法剤の同時投与レジメン
EP3976658A4 (en) * 2019-05-24 2023-06-07 Forty Seven, Inc. Regimes for co-administration of immunotherapeutic agents against c-kit and cd47
WO2020242895A1 (en) * 2019-05-24 2020-12-03 Forty Seven, Inc. Regimes for co-administration of immunotherapeutic agents against c-kit and cd47
WO2020247820A1 (en) 2019-06-07 2020-12-10 ALX Oncology Inc. Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
WO2020263830A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
EP4003375A4 (en) * 2019-07-31 2023-09-06 Forty Seven, Inc. DEPLETION DIETS FOR MODIFIED T CELL OR NK CELL THERAPY
EP4349413A2 (en) 2019-10-18 2024-04-10 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
WO2021076908A1 (en) 2019-10-18 2021-04-22 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
WO2021087064A1 (en) 2019-10-31 2021-05-06 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
WO2021108693A1 (en) 2019-11-27 2021-06-03 ALX Oncology Inc. Combination therapies for treating cancer
JP7672172B2 (ja) 2019-12-24 2025-05-07 ラノバ メディシンズ リミテッド 抗ＳＩＲＰαモノクローナル抗体およびその使用
CN114040925A (zh) * 2019-12-24 2022-02-11 礼新医药科技(上海)有限公司 抗SIRPα单克隆抗体及其用途
JP2023508065A (ja) * 2019-12-24 2023-02-28 ラノバ メディシンズ リミテッド 抗ＳＩＲＰαモノクローナル抗体およびその使用
WO2021130638A1 (en) 2019-12-24 2021-07-01 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
CN114040925B (zh) * 2019-12-24 2023-04-28 礼新医药科技(上海)有限公司 抗SIRPα单克隆抗体及其用途
JP7437815B2 (ja) 2019-12-24 2024-02-26 ラノバ メディシンズ リミテッド 抗ＳＩＲＰαモノクローナル抗体およびその使用
EP4445902A2 (en) 2019-12-24 2024-10-16 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
JP2024042083A (ja) * 2019-12-24 2024-03-27 ラノバ メディシンズ リミテッド 抗ＳＩＲＰαモノクローナル抗体およびその使用
JP7672172B6 (ja) 2019-12-24 2025-06-19 ラノバ メディシンズ リミテッド 抗ＳＩＲＰαモノクローナル抗体およびその使用
US11692038B2 (en) 2020-02-14 2023-07-04 Gilead Sciences, Inc. Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)
WO2021163064A2 (en) 2020-02-14 2021-08-19 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
US12297282B2 (en) 2020-02-14 2025-05-13 Gilead Sciences, Inc. Nucleic acids encoding, and methods of producing, antibodies that bind human chemokine (C—C motif) receptor 8 (CCR8)
WO2021236658A1 (en) 2020-05-19 2021-11-25 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
US12146000B2 (en) 2020-05-19 2024-11-19 Boehringer Ingelheim International Gmbh Bispecific and tetravalent CD137 and FAP molecules for the treatment of cancer
US12343377B2 (en) 2020-06-01 2025-07-01 ALX Oncology Inc. Combination therapies comprising a hypomethylation agent for treating cancer
WO2021247430A1 (en) 2020-06-01 2021-12-09 ALX Oncology Inc. Combination therapies comprising a hypomethylation agent for treating cancer
WO2022087149A2 (en) 2020-10-22 2022-04-28 Gilead Sciences, Inc. Interleukin-2-fc fusion proteins and methods of use
WO2022098642A1 (en) 2020-11-03 2022-05-12 Rdiscovery, LLC Therapies for treatment of cancer and phagocytosis-deficiency related diseases
EP4253416A4 (en) * 2020-11-30 2024-11-13 Qure Biotechnology (Shanghai) Co., Ltd. ANTI-SIRPALPHA ANTIBODY OR ASSOCIATED ANTIGEN-BINDING FRAGMENT, AND USE THEREOF
WO2022120286A1 (en) 2020-12-06 2022-06-09 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
EP4261223A4 (en) * 2020-12-11 2024-11-13 BioRay Pharmaceutical Co., Ltd. ANTI-SIRP? ANTIBODIES AND THEIR APPLICATION
WO2022221304A1 (en) 2021-04-14 2022-10-20 Gilead Sciences, Inc. CO-INHIBITION OF CD47/SIRPα BINDING AND NEDD8-ACTIVATING ENZYME E1 REGULATORY SUBUNIT FOR THE TREATMENT OF CANCER
US12098214B2 (en) 2021-05-13 2024-09-24 ALX Oncology Inc. Combination therapies for treating cancer
WO2022241157A1 (en) 2021-05-13 2022-11-17 ALX Oncology Inc. Combination therapies for treating cancer
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
US11572412B2 (en) 2021-06-04 2023-02-07 Boehringer Ingelheim International Gmbh Anti-SIRP-alpha antibodies
WO2022254379A1 (en) 2021-06-04 2022-12-08 Boehringer Ingelheim International Gmbh Anti-sirp-alpha antibodies
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023278377A1 (en) 2021-06-29 2023-01-05 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
WO2023012350A1 (en) 2021-08-05 2023-02-09 Immunos Therapeutics Ag Combination medicaments comprising hla fusion proteins
WO2023076983A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
WO2023077030A1 (en) 2021-10-29 2023-05-04 Gilead Sciences, Inc. Cd73 compounds
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023122581A2 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023147418A1 (en) 2022-01-28 2023-08-03 Gilead Sciences, Inc. Parp7 inhibitors
EP4245756A1 (en) 2022-03-17 2023-09-20 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023178181A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
EP4464703A2 (en) 2022-03-17 2024-11-20 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023183817A1 (en) 2022-03-24 2023-09-28 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2023196784A1 (en) 2022-04-05 2023-10-12 Gilead Sciences, Inc. Combinations of antibody therapies for treating colorectal cancer
WO2023205719A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023235754A1 (en) 2022-06-01 2023-12-07 ALX Oncology Inc. Combination therapies for treating urothelial carcinoma
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
WO2024003353A1 (en) 2022-07-01 2024-01-04 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024105180A1 (en) 2022-11-16 2024-05-23 Boehringer Ingelheim International Gmbh Predictive efficacy biomarkers for anti-sirpa antibodies
WO2024137852A1 (en) 2022-12-22 2024-06-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024165671A1 (en) 2023-02-08 2024-08-15 Immunos Therapeutics Ag FUSION PROTEINS OF ß2 MICROGLOBULIN, HLA HEAVY CHAIN POLYPEPTIDES, AND INHIBITOR OF CD47-SIRPA
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025006720A1 (en) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Kras modulating compounds
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
WO2025024663A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025202222A1 (en) 2024-03-25 2025-10-02 Institut National de la Santé et de la Recherche Médicale Therapeutic use of sting and tlrs agonists to induce p16 expression in immune cells
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Also Published As

Publication number Publication date
AU2022204618A1 (en) 2022-07-21
PL3658589T3 (pl) 2024-03-18
AU2018308364A1 (en) 2020-03-12
EP3658589B1 (en) 2023-09-27
CA3071193A1 (en) 2019-01-31
US10961318B2 (en) 2021-03-30
US20210171654A1 (en) 2021-06-10
ES2963157T3 (es) 2024-03-25
KR102670957B1 (ko) 2024-05-31
JP2020528752A (ja) 2020-10-01
US11753480B2 (en) 2023-09-12
MX2020000957A (es) 2020-07-22
KR20200067833A (ko) 2020-06-12
JP7383074B2 (ja) 2023-11-17
BR112020001653A2 (pt) 2020-07-21
JP7122370B2 (ja) 2022-08-19
CN111448210B (zh) 2024-05-14
CN111448210A (zh) 2020-07-24
IL272218A (en) 2020-03-31
JP2022097652A (ja) 2022-06-30
AU2022204618B2 (en) 2025-02-27
AU2018308364B2 (en) 2022-04-28
AU2018308364C1 (en) 2023-02-16
EP3658589C0 (en) 2023-09-27
US20190119396A1 (en) 2019-04-25
SG11202000658PA (en) 2020-02-27
EP3658589A1 (en) 2020-06-03

Similar Documents

Publication Publication Date Title
AU2022204618B2 (en) Anti-SIRP-alpha antibodies and related methods
AU2021202966B2 (en) Humanized, mouse or chimeric anti-CD47 monoclonal antibodies
US20240124588A1 (en) Compositions and methods for disabling myeloid cells expressing trem1
CN110352200B (zh) 抗具有Ig和ITIM结构域的T细胞免疫受体(TIGIT)的抗体及其应用
KR102878970B1 (ko) 항-SIRPalpha 항체 요법의 대식세포 증진 효능에서 Fc 수용체 참여의 붕괴
CN112566935B (zh) 抗ox40抗体和使用方法
CN115768792A (zh) 抗ccr8抗体用于治疗癌症
EP3337826A1 (en) Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies
WO2023288241A1 (en) Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
WO2020112781A1 (en) Antibodies comprising modified heavy constant regions
KR20220103105A (ko) 항-tim3 항체와 병용하여 항-ox40 항체를 사용한 암 치료 방법
HK40031044A (en) Anti-sirp-alpha antibodies and related methods
HK40031044B (en) Anti-sirp-alpha antibodies and related methods
HK40030237B (zh) 抗SIRP-α抗体及相关方法
HK40030237A (en) Anti-sirp-alpha antibodies and related methods

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18765224

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3071193

Country of ref document: CA

Ref document number: 2020504234

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020001653

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2018308364

Country of ref document: AU

Date of ref document: 20180725

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018765224

Country of ref document: EP

Effective date: 20200226

ENP Entry into the national phase

Ref document number: 112020001653

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20200124